Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and ophthalmic viscoelastic products (e.g., AMVISC, CoEase). The company operates primarily in the United States with significant international distribution.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenue | $7,291,000 | $6,141,000 |
| Product Revenue | $5,677,000 | $5,569,000 |
| License & Milestone Revenue | $1,614,000 | $572,000 |
| Gross Profit | $4,297,000 | $3,420,000 |
| Gross Margin (Total) | 58.9% | 55.7% |
| Net Income | $1,202,000 | $7,786,000 |
| Diluted EPS | $0.11 | $0.69 |
| Cash and Equivalents (End of Period) | $40,337,000 | $34,499,000 |
| Operating Cash Flow | $930,000 | $19,568,000 |
| Total Debt | $0 | $0 |
Note: Q1 2004 Net Income included a one-time $7.0 million tax benefit from the release of a valuation allowance, which is not present in Q1 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18.7% year-over-year, driven primarily by a 182% increase in license and milestone revenue due to the ratable recognition of upfront payments from the Ortho Biotech agreement.
- Product Revenue Mix:
- Ophthalmic Products: Increased 16.6% to $2.77 million, largely due to a 54.5% sales increase to Bausch & Lomb under a new supply agreement.
- ORTHOVISC: Increased 5.5% to $2.40 million. International sales surged 98.1% (Turkey/Canada), offsetting a 47.4% decline in U.S. sales to Ortho Biotech due to lower distributor stocking levels post-launch.
- HYVISC: Decreased 44.9% to $507,000 due to distributor inventory patterns.
- Profitability: Net income decreased significantly ($6.6 million drop) compared to Q1 2004, primarily because the prior year included a non-recurring $7.0 million tax benefit. Operating income, however, increased 50% to $1.8 million.
- Cash Flow: Operating cash flow dropped to $930,000 from $19.6 million in the prior year, as the previous period included a $20 million milestone payment from Ortho Biotech recorded as deferred revenue.
Outlook, Risks, and Management Commentary
- Reimbursement Challenges: U.S. sales of ORTHOVISC are impacted by the lack of a unique reimbursement code (J code) for physician offices. While a unique code (C code) exists for outpatient hospital settings, the absence of a J code may limit physician adoption. A new application was submitted in January 2005 for a 2006 effective date.
- Strategic Partnerships:
- Bausch & Lomb: A new 6-year supply agreement (through 2010) secures exclusive global supply (excluding Japan) for AMVISC products, with pricing adjustments starting in 2005.
- Advanced Medical Optics: The distribution agreement for CoEase is set to expire in June 2005 and will not be renewed following their acquisition of a competing product line. Sales to this customer have already dropped to less than 1% of revenue.
- DePuy Mitek: A new Johnson & Johnson entity will begin selling ORTHOVISC in the U.S. in Q2 2005, focusing on arthroscopists, while Ortho Biotech retains rheumatology focus.
- R&D Pipeline:
- CTA (Cosmetic Tissue Augmentation): Pivotal clinical trial enrollment completed; PMA application expected by Q3 2005.
- INCERT-S: Pilot human clinical trial for adhesion prevention ongoing in the U.K.; enrollment expected by Q2 2005.
- Accounting Changes: The company plans to adopt SFAS 123(R) regarding share-based compensation prospectively in Q1 2006, which will introduce non-cash expenses.
- Risk Factors: Heavy reliance on a small number of customers (top 3 accounted for 77.7% of product revenue in Q1 2005); regulatory approval risks for new products; and potential manufacturing disruptions.
Investor Verification Checklist
- Reimbursement Status: Verify the status of the unique J code application for ORTHOVISC in physician offices and its potential impact on U.S. sales growth.
- Customer Concentration: Assess the risk associated with the top three customers representing 77.7% of product revenue, specifically the expiration of the Advanced Medical Optics contract in June 2005.
- Revenue Recognition: Review the amortization schedule of the $27 million deferred revenue from the Ortho Biotech agreement to understand future recurring revenue stability.
- Clinical Trial Milestones: Monitor the completion of the CTA pivotal trial and the submission of the PMA application expected in late 2005.
- Debt and Liquidity: Confirm the company's cash burn rate relative to its $40.3 million cash position, noting the absence of long-term debt.